$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Generic version of sotorazeb: a new affordable treatment option
2026-02-01 22:25:32
Check Details
Interpreting the price war for generic sotorasib: How do patients benefit?
2026-02-01 22:25:32
Check Details
Laos Lucius and Daxiong generic drugs cut prices, changing the competitive landscape of Sotolasibu market
2026-02-01 22:25:32
Check Details
How long does it take for Eltrombopag/Eltrombopag to increase platelets?
2026-02-01 22:25:32
Check Details
Eltrombopag/eltrombopag dose reduction and discontinuation criteria
2026-02-01 22:25:32
Check Details
Application and precautions of Eltrombopag/Eltrombopag in special groups (such as pregnant women and children)
2026-02-01 22:25:32
Check Details
Medication Instructions for Patients: How to Determine the Dosage of Eltrombopag/Eltrombopag
2026-02-01 22:25:32
Check Details
Eltrombopag/eltrombopag treatment cycle and discontinuation observation
2026-02-01 22:25:32
Check Details
Effect and time of eltrombopag/eltrombopag on increasing platelets
2026-02-01 22:25:32
Check Details
Eltrombopag/eltrombopag dose adjustment and discontinuation guidelines
2026-02-01 22:25:32
Check Details
Guidance and safety warnings for the use of Eltrombopag/Eltrombopag in pregnant women, children and other special groups
2026-02-01 22:25:32
Check Details
How to buy cabozantinib in the country?
2026-02-01 22:25:32
Check Details
1
2
...
573
574
575
576
577
578
579
...
10223
10224
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib Clinical Guide: Drug Comparisons, Treatment Strategies, and Combination Therapy Prospects
2
Avatrombopag Complete Guide: Efficacy, Indications, and TPO-RA Drug Comparisons
3
Pralsetinib Clinical Guide: Discontinuation Principles, Drug Comparisons, and Treatment Strategies
4
Venetoclax Clinical Guide: Mechanism, Indications, and Originator vs. Generic Comparison
5
Dabrafenib Clinical Guide: Indications, Combination Strategies, and BRAF Inhibitor Comparisons
6
Elagolix Side Effects and Safety Guide
7
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
8
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
9
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
10
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
11
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
12
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management